Human disease models

The US Food and Drug Administration’s (FDA) Research to Accelerate Cures and Equity (RACE) for Children Act now requires all oncology drugs to be tested for paediatric indications ahead of approval. The EU regulation of the European Medicines Agency (EMA) is also being adapted to mirror the FDA’s regulations. In response, Charles River Laboratories is […]

A considerable roadblock in the successful triaging of new therapeutics for liver and metabolic related diseases is the reliability and effectiveness of pre-clinical disease models. Methods employing animal models may have limited success in replicating liver diseases, primarily because of species-specific differences, furthermore, the utilisation of animal models to simulate liver disease phenotypes frequently leads […]

A considerable roadblock in the successful triaging of new therapeutics for liver and metabolic related diseases is the reliability and effectiveness of pre-clinical disease models. Methods employing animal models may have limited success in replicating liver diseases, primarily because of species-specific differences, furthermore, the utilisation of animal models to simulate liver disease phenotypes frequently leads […]

A considerable roadblock in the successful triaging of new therapeutics for liver and metabolic related diseases is the reliability and effectiveness of pre-clinical disease models. Methods employing animal models may have limited success in replicating liver diseases, primarily because of species-specific differences, furthermore, the utilisation of animal models to simulate liver disease phenotypes frequently leads […]

A considerable roadblock in the successful triaging of new therapeutics for liver and metabolic related diseases is the reliability and effectiveness of pre-clinical disease models. Methods employing animal models may have limited success in replicating liver diseases, primarily because of species-specific differences, furthermore, the utilisation of animal models to simulate liver disease phenotypes frequently leads […]

A considerable roadblock in the successful triaging of new therapeutics for liver and metabolic related diseases is the reliability and effectiveness of pre-clinical disease models. Methods employing animal models may have limited success in replicating liver diseases, primarily because of species-specific differences, furthermore, the utilisation of animal models to simulate liver disease phenotypes frequently leads […]

A considerable roadblock in the successful triaging of new therapeutics for liver and metabolic related diseases is the reliability and effectiveness of pre-clinical disease models. Methods employing animal models may have limited success in replicating liver diseases, primarily because of species-specific differences, furthermore, the utilisation of animal models to simulate liver disease phenotypes frequently leads […]

Researchers at University of Michigan (U-M) have developed a method to produce human brain organoids without animal cells that could improve the way neurodegenerative conditions are studied and treated. Human brain organoids are derived from embryonic or pluripotent stem cells and more closely model the complex brain structure compared to conventional two-dimensional cultures. Until now, […]

Humanization of highly immunodeficient NSG mice with hematopoietic stem cells or peripheral blood mononuclear cells provides a powerful platform for very precise modeling of human immune responses. These immune-humanized platforms enable researchers to test a wide range of human-specific therapeutic approaches developed to either up or down regulate immune function. Join DDW for this exclusive […]

This article is sponsored by Charles River. Research tools, safety testing and regenerative medicines – these endless stem cell applications are powering precision, speed, and new modalities in drug development.     Stem cells for use in drug discovery Stem cells are fast becoming an invaluable tool in the drug discovery process. Through the use of human induced […]

Humanization of highly immunodeficient NSG mice with hematopoietic stem cells or peripheral blood mononuclear cells provides a powerful platform for very precise modeling of human immune responses. These immune-humanized platforms enable researchers to test a wide range of human-specific therapeutic approaches developed to either up or down regulate immune function. Join DDW for this exclusive […]

Humanization of highly immunodeficient NSG mice with hematopoietic stem cells or peripheral blood mononuclear cells provides a powerful platform for very precise modeling of human immune responses. These immune-humanized platforms enable researchers to test a wide range of human-specific therapeutic approaches developed to either up or down regulate immune function. Join DDW for this exclusive […]

Humanization of highly immunodeficient NSG mice with hematopoietic stem cells or peripheral blood mononuclear cells provides a powerful platform for very precise modeling of human immune responses. These immune-humanized platforms enable researchers to test a wide range of human-specific therapeutic approaches developed to either up or down regulate immune function. Join DDW for this exclusive […]

Humanization of highly immunodeficient NSG mice with hematopoietic stem cells or peripheral blood mononuclear cells provides a powerful platform for very precise modeling of human immune responses. These immune-humanized platforms enable researchers to test a wide range of human-specific therapeutic approaches developed to either up or down regulate immune function. Join DDW for this exclusive […]

Humanization of highly immunodeficient NSG mice with hematopoietic stem cells or peripheral blood mononuclear cells provides a powerful platform for very precise modeling of human immune responses. These immune-humanized platforms enable researchers to test a wide range of human-specific therapeutic approaches developed to either up or down regulate immune function. During this webinar, supported by […]

Following the Scottish Research and Drug Development Forum meeting, DDW’s Diana Spencer provides a snapshot of drug discovery in Scotland. With over 150 pharma services/supply companies and 19 universities, Scotland is one of the most advanced life science sectors in the UK and the world. To demonstrate how Scotland is continuing to innovate and shape […]